Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of intraperitoneal catumaxomab in EpCAM-positive cancer with malignant ascites
2005-001700-39Phase 2Completed
- Sponsor
- Fresenius
- Start
- Jul 2005
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of catumaxomab in malignant ascites and Nonhematologic neoplasms, sponsored by Fresenius. Primary endpoints: Systemic exposure of catumaxomab, Pharmacokinetic characterization of catumaxomab and 2 more. Started Jul 2005; status: completed.
02
Drugs
catumaxomab
03
Conditions
malignant ascitesNonhematologic neoplasms
Beyond the preview
Go deeper on 2005-001700-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001700-39.